Abstract 16757: Early Ambulation Among Hospitalized Heart Failure Patients is Associated With Decreased Length of Stay and Higher Rates of Discharge to Home
Introduction: Older patients hospitalized with heart failure (HF) often have multiple comorbidities contributing to longer length of stays (LOS) and high rates of discharge to subacute care. Early ambulation (EA) has been associated with improved outcomes for other conditions. Whether the same association exists for HF is unknown.
Hypothesis: We hypothesized that EA, defined as mobilization within 2 days of hospitalization, is associated with reduced length of stay (LOS) and more favorable discharge disposition for patients with HF.
Methods: The study population included 285,653 inpatients with HF at 369 hospitals enrolled in Get With The Guidelines-HF from 2009 through 2015. We used multivariate logistic regression with generalized estimating equations to identify predictors of EA and determine the association between EA and LOS and discharge disposition.
Results: The study population included 49% women, the median age was 75, and 68% were white. Sixty five percent of patients ambulated by day 2 of the hospital admission. There were large differences in age and comorbid conditions by EA status. In multivariate analysis, predictors of EA included age, gender, and hospitalization outside of the northeast (P<0.01 for all). Hospital size and academic status were not predictive. After adjustment, we found that adherence to the EA performance measure was associated with a 24.3% decrease in adjusted length of stay, and 3.7 times the odds of being discharged to home compared to no EA. (Table).
Conclusions: EA among hospitalized HF patients may be associated with shorter LOS and greater likelihood of discharge to home. Further prospective study is needed to confirm these associations.
Author Disclosures: L.M. Fleming: None. X. Zhao: None. A.D. Devore: Other Research Support; Modest; Amgen, American Heart Association, Novartis. P.A. Heidenreich: None. C.W. Yancy: None. G.C. Fonarow: Consultant/Advisory Board; Modest; Amgen, Janssen. Consultant/Advisory Board; Significant; Novartis. A.F. Hernandez: Other Research Support; Modest; Amgen, AstraZeneca, Bayer, Merck, Novartis. Honoraria; Modest; AstraZeneca, Boston Scientific, Novartis. R.D. Kociol: None.
- © 2016 by American Heart Association, Inc.